Fabiana Cancrini1,2, Floriane Michel3,4, Olivier Cussenot4, Hussa Alshehhi4,5, Eva Comperat4,5, Véronique Phé4. 1. Department of Medical and Surgical Sciences and Translational Medicine, Sapienza Univeristà di Roma, Sant 'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. fabiana.cancrini@gmail.com. 2. Sorbonne University, GRC n°5, ONCOTYPE-URO, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. fabiana.cancrini@gmail.com. 3. Department of Urology and Kidney Transplantation, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France. 4. Sorbonne University, GRC n°5, ONCOTYPE-URO, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. 5. Department of Pathology, Tenon Hospital, AP-HP. Sorbonne University, Paris, France.
Abstract
PURPOSE: The aim of our study was to evaluate and compare the expression of different immunohistochemical markers in Bladder Carcinomas (BC) in patients with Neurogenic Bladder (NB) and Urinary Schistosomiasis (US) infection. MATERIALS AND METHODS: We collected tissue samples from patients with Neurogenic Bladder and Bladder Carcinoma (NBC Group) and from patients with Urinary Schistosomiasis infection and Bladder Carcinoma (SBC Group). We compared to these two groups to control samples from resection from patients with Urinary Schistosomiasis without Bladder Carcinoma (US Group); we also investigate patients' characteristics according to urothelial transitional cell carcinoma (TCC), and squamous cell carcinoma (SCC) histopathological differentiation. The expression of markers in all groups (CK7, CK14, CK20, FoxP3, GATA3, STAG2, CD3, CD8, Ki67, and P53) was analyzed using immunohistochemistry of tissue micro-array sections (TMA). RESULTS: Overall, 136 patients were included in the study (n = 72 in the NBC group, n = 33 in the SBC group, and n = 31 in the US group). In the TCC subgroup, the expression of CK7, CK14, CK20, and Ki67 was significantly higher compared to US controls (p 0.002; p < 0.001; p 0.036; p < 0.001). In the SCC subgroup, the expression of CK7, CK14, and CK20 was significantly higher compared to US controls (p 0.007; p < 0.001; p 0.005). Both in TCC and SCC subgroups, no difference in the expression of any tested markers was found comparing NBC and SBC groups. In US group, a significant higher expression of STAG2 was found compared to SCC subgroup (p 0.005). CONCLUSION: Based on our results, the profile of immunohistochemical biomarkers' expression in both NBC and SBC groups is similar.
PURPOSE: The aim of our study was to evaluate and compare the expression of different immunohistochemical markers in Bladder Carcinomas (BC) in patients with Neurogenic Bladder (NB) and Urinary Schistosomiasis (US) infection. MATERIALS AND METHODS: We collected tissue samples from patients with Neurogenic Bladder and Bladder Carcinoma (NBC Group) and from patients with Urinary Schistosomiasis infection and Bladder Carcinoma (SBC Group). We compared to these two groups to control samples from resection from patients with Urinary Schistosomiasis without Bladder Carcinoma (US Group); we also investigate patients' characteristics according to urothelial transitional cell carcinoma (TCC), and squamous cell carcinoma (SCC) histopathological differentiation. The expression of markers in all groups (CK7, CK14, CK20, FoxP3, GATA3, STAG2, CD3, CD8, Ki67, and P53) was analyzed using immunohistochemistry of tissue micro-array sections (TMA). RESULTS: Overall, 136 patients were included in the study (n = 72 in the NBC group, n = 33 in the SBC group, and n = 31 in the US group). In the TCC subgroup, the expression of CK7, CK14, CK20, and Ki67 was significantly higher compared to US controls (p 0.002; p < 0.001; p 0.036; p < 0.001). In the SCC subgroup, the expression of CK7, CK14, and CK20 was significantly higher compared to US controls (p 0.007; p < 0.001; p 0.005). Both in TCC and SCC subgroups, no difference in the expression of any tested markers was found comparing NBC and SBC groups. In US group, a significant higher expression of STAG2 was found compared to SCC subgroup (p 0.005). CONCLUSION: Based on our results, the profile of immunohistochemical biomarkers' expression in both NBC and SBC groups is similar.
Authors: Alana Lelo; Frederik Prip; Brent T Harris; David Solomon; Deborah L Berry; Krysta Chaldekas; Anagha Kumar; Jeffry Simko; Jørgen Bjerggaard Jensen; Pritish Bhattacharyya; Ciaran Mannion; Jung-Sik Kim; George Philips; Lars Dyrskjøt; Todd Waldman Journal: Clin Cancer Res Date: 2018-06-28 Impact factor: 12.531
Authors: William Dubinski; Manal Gabril; Vladimir V Iakovlev; Andreas Scorilas; Youssef M Youssef; Hala Faragalla; Kalman Kovacs; Fabio Rotondo; Shereen Metias; Androu Arsanious; Anna Plotkin; Andrew H F Girgis; Catherine J Streutker; George M Yousef Journal: Hum Pathol Date: 2011-12-26 Impact factor: 3.466
Authors: Farhad Islami; Carmen E Guerra; Adair Minihan; K Robin Yabroff; Stacey A Fedewa; Kirsten Sloan; Tracy L Wiedt; Blake Thomson; Rebecca L Siegel; Nigar Nargis; Robert A Winn; Lisa Lacasse; Laura Makaroff; Elvan C Daniels; Alpa V Patel; William G Cance; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2021-12-08 Impact factor: 508.702
Authors: David A Solomon; Jung-Sik Kim; Jolanta Bondaruk; Shahrokh F Shariat; Zeng-Feng Wang; Abdel G Elkahloun; Tomoko Ozawa; Julia Gerard; Dazhong Zhuang; Shizhen Zhang; Neema Navai; Arlene Siefker-Radtke; Joanna J Phillips; Brian D Robinson; Mark A Rubin; Björn Volkmer; Richard Hautmann; Rainer Küfer; Pancras C W Hogendoorn; George Netto; Dan Theodorescu; C David James; Bogdan Czerniak; Markku Miettinen; Todd Waldman Journal: Nat Genet Date: 2013-10-13 Impact factor: 38.330
Authors: Klaus Golka; Ralf Böthig; Wobbeke Weistenhöfer; Olaf P Jungmann; Steffi Bergmann; Michael Zellner; Wolfgang Schöps Journal: Urologie Date: 2022-09-26